Dark

AXGN
Axogen, Inc. Common Stock
stock NASDAQ

At Close

Jul 31, 2026 3:59:52 PM EDT

42.15USD+1.885%(+0.78)1,223,540

30.89Bid 50.73Ask 19.84Spread

Pre-market

Jul 31, 2026 9:28:30 AM EDT

41.05USD-0.774%(-0.32)6,221

After-hours

Jul 31, 2026 4:27:30 PM EDT

42.00USD-0.356%(-0.15)148,186

OverviewOptionsHistoricalExchangesShortsNews

Jan 10, 2022

07:31AM EST Axogen Sees Q4 Sales ~$31.5M Vs. $31.91M Est., FY21 Sales ~$127.3M Vs. $127.79M Est. Benzinga

07:00AM EST Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2021 revenue. GlobeNewswire Inc

Jan 4, 2022

07:00AM EST Axogen to Participate at AAHS ASPN ASRM 2022 Annual Meetings GlobeNewswire Inc

Dec 15, 2021

11:42AM EST Watching Turning Point Brands, Axogen, Gaia Shares Following TipRanks Article '3 Stocks That Are Flirting With a Bottom; Analysts Say 'Buy'' Benzinga

07:00AM EST Axogen sponsors 2022 Donate Life Rose Parade GlobeNewswire Inc

Nov 10, 2021

07:00AM EST Axogen, Inc. to Participate at Canaccord Genuity Virtual MedTech, GlobeNewswire Inc

Nov 4, 2021

09:40AM EDT JMP Securities Maintains Market Outperform on Axogen, Lowers Price Target to $20 Benzinga

07:00AM EDT Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO and president, will present at the Jefferies London Healthcare Conference. The presentation is scheduled for Wednesday, November 17, 2021 at 4:25 p.m. (11:25 a.m. ET). GlobeNewswire Inc

Nov 3, 2021

05:34PM EDT Axogen: Q3 Earnings Insights Benzinga

04:56PM EDT Axogen Cuts FY21 Sales Guidance From $134.5M-$137.5M To $127M-$129M Vs. $135.29M Est. Benzinga

04:55PM EDT Axogen Q3 EPS $(0.09) Beats $(0.13) Estimate, Sales $31.20M Miss $34.65M Estimate Benzinga

04:01PM EDT Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the third quarter ended September 30, 2021. GlobeNewswire Inc

09:10AM EDT Earnings Scheduled For November 3, 2021 Benzinga

Oct 19, 2021

09:35AM EDT AxoGen Granted U.S. Patent Titled 'Materials and methods for nerve repair with animal-sourced grafts' Benzinga

Oct 13, 2021

07:00AM EDT Axogen, Inc. to Report Third Quarter Financial Results and Host GlobeNewswire Inc

Sep 22, 2021

07:00AM EDT Axogen to Participate in the 76th Annual Meeting of the American GlobeNewswire Inc

Sep 1, 2021

07:05AM EDT Axogen RECON Clinical Study Completes Subject Follow-up Benzinga

07:00AM EDT Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that the RECON Clinical Study supporting its Biologics License Application (BLA) for Avance Nerve Graft has completed follow-up of study subjects. GlobeNewswire Inc

Aug 4, 2021

04:48PM EDT Axogen Raises FY21 Sales Guidance From $133M-$136M To $134.5M-$137.5M Vs. $134.03M Est. Benzinga

04:47PM EDT Axogen Q2 EPS $(0.09) Beats $(0.13) Estimate, Sales $33.60M Beat $32.24M Estimate Benzinga

04:01PM EDT Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended June 30, 2021. GlobeNewswire Inc

07:52AM EDT The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings Benzinga

04:10AM EDT Earnings Scheduled For August 4, 2021 Benzinga

Aug 3, 2021

11:06AM EDT Preview: Axogen's Earnings Benzinga

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 22, 2021

07:00AM EDT Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president will present at the Canaccord Genuity 41st Annual Growth Conference. The virtual presentation is scheduled for Wednesday, August 11, 2021 at 1:00 p.m. ET. GlobeNewswire Inc

Jul 19, 2021

04:01PM EDT Axogen, Inc. Appoints John H. Johnson to Board of Directors GlobeNewswire Inc

Jul 14, 2021

07:00AM EDT Axogen, Inc. to Report Second Quarter Financial Results and Host GlobeNewswire Inc

May 18, 2021

08:43AM EDT Axogen To Stop Commercial Sales Of Avive Soft Tissue Membrane Pending Discussions With FDA Benzinga

07:00AM EDT Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president and Peter J. Mariani, executive vice president and CFO will present at two upcoming investor conferences. GlobeNewswire Inc

May 17, 2021

05:04PM EDT Axogen To Suspend Market Availability Of Avive Soft Tissue Membrane Pending Regulatory Classification By FDA; Reaffirms FY21 Guidance Benzinga

May 6, 2021

12:16PM EDT Canaccord Genuity Maintains Hold on Axogen, Raises Price Target to $24 Benzinga

07:00AM EDT Axogen, Inc. to Present at the Canaccord Genuity Musculoskeletal GlobeNewswire Inc

May 5, 2021

04:49PM EDT Recap: Axogen Q1 Earnings Benzinga

04:02PM EDT Axogen Sees FY21 Sales $133M-$136M Vs $125.7M Estimates Benzinga

04:00PM EDT Axogen Q1 EPS $(0.08) Beats $(0.16) Estimate, Sales $31.00M Beat $27.88M Estimate Benzinga

04:00PM EDT Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2021. GlobeNewswire Inc

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

04:16AM EDT Earnings Scheduled For May 5, 2021 Benzinga

Apr 14, 2021

07:00AM EDT Axogen, Inc. to Report First Quarter Financial GlobeNewswire Inc

Mar 1, 2021

04:08PM EST Axogen Announces The Promotion Of Peter J. Mariani To CFO Benzinga

04:01PM EST Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the promotion of Peter J. Mariani to Executive Vice President and Chief Financial Officer. GlobeNewswire Inc

Feb 24, 2021

07:30AM EST The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO Benzinga

Feb 23, 2021

09:39AM EST Canaccord Genuity Maintains Hold on Axogen, Raises Price Target to $21 Benzinga

07:41AM EST 10 Biggest Price Target Changes For Tuesday Benzinga

07:25AM EST The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts Benzinga

04:45AM EST SVB Leerink Maintains Outperform on Axogen, Raises Price Target to $27 Benzinga

Feb 22, 2021

04:02PM EST Axogen Q4 Adj. EPS $(0.08) Beats $(0.12) Estimate, Sales $32.50M Beat $29.83M Estimate Benzinga

04:01PM EST Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2020. GlobeNewswire Inc

04:02AM EST Earnings Scheduled For February 22, 2021 Benzinga

Feb 19, 2021

10:16AM EST A Preview Of Axogen's Earnings Benzinga

Feb 18, 2021

07:06AM EST Axogen Sponsored REPOSE Study Completes Pilot Phase Analysis Benzinga

Feb 4, 2021

07:00AM EST Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced it will participate in two investor conferences in February. GlobeNewswire Inc

Feb 1, 2021

07:00AM EST Axogen, Inc. to Report Fourth Quarter and Full-Year 2020 Financial GlobeNewswire Inc

Jan 11, 2021

07:10AM EST Axogen Sees Q4 Revenue To Be At Least $32.4 Mln; Increases Active Accounts To 893 RTTNews

07:10AM EST Axogen Sees Prelim. Q4 Sales $32.4M+ vs $29.52M Est., Sees Prelim. FY20 Sales $112.2M+ vs $109.33M Est. Benzinga

Jan 8, 2021

07:25AM EST The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs Benzinga

Jan 5, 2021

07:00AM EST Axogen to Participate at AAHS ASPN ASRM 2021 Virtual Annual Meetings GlobeNewswire Inc

Dec 23, 2020

07:00AM EST Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, announced today their sponsorship of Donate Life at the annual Tournament of Roses celebration. For 2021, the Rose Parade will be held as a televised special in Pasadena, CA on New Years Day. GlobeNewswire Inc

Nov 4, 2020

07:00AM EST Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at two upcoming investor events the Jefferies Virtual London Healthcare Conference and the Canaccord Genuity Virtual MedTech & Diagnostics Forum. GlobeNewswire Inc

Oct 30, 2020

10:32AM EDT Axogen shares are trading higher after the company reported better-than-expected Q3 EPS and sales results. Benzinga

08:09AM EDT The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts Benzinga

Oct 29, 2020

04:17PM EDT Axogen Q3 EPS $0.04 Beats $(0.16) Estimate, Sales $33.40M Beat $24.52M Estimate Benzinga

07:30AM EDT The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal Benzinga

04:08AM EDT Earnings Scheduled For October 29, 2020 Benzinga

Oct 28, 2020

10:15AM EDT Earnings Outlook For Axogen Benzinga

Oct 23, 2020

10:48AM EDT Benzinga's Top Upgrades, Downgrades For October 23, 2020 Benzinga

06:02AM EDT Guggenheim Initiates Coverage On Axogen with Buy Rating, Announces Price Target of $24 Benzinga

Oct 8, 2020

07:00AM EDT Axogen, Inc. to Report Third Quarter 2020 Financial Results and GlobeNewswire Inc

Sep 30, 2020

04:02PM EDT Axogen Appoints Paul Thomas To Board Of Directors RTTNews

04:01PM EDT Healthcare veteran brings 30+ years of medtech experience to Axogen, Inc. Board of Directors GlobeNewswire Inc

Sep 25, 2020

07:00AM EDT Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at the JMP Securities MedTech Bio Summit. Axogens presentation during this virtual summit is scheduled for Thursday, October 1, 2020 at 11:00 a.m. ET. GlobeNewswire Inc

Sep 24, 2020

07:00AM EDT Axogen to Participate in the 75th AnnualAmerican GlobeNewswire Inc

Sep 16, 2020

10:18AM EDT Shares of surgical solutions developer AxoGen, Inc. (AXGN) are rising more than 20% Wednesday morning after raising third-quarter revenue guidance. RTTNews

Aug 31, 2020

07:00AM EDT Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president will present at the Cantor Virtual Global Healthcare Conference. The virtual presentation is scheduled for Wednesday, September 16, 2020 at 1:20 p.m. ET. GlobeNewswire Inc

Aug 6, 2020

06:49AM EDT SVB Leerink Maintains Outperform on Axogen, Raises Price Target to $15.5 Benzinga

Aug 5, 2020

04:04PM EDT Axogen Q2 EPS $(0.15) Beats $(0.38) Estimate, Sales $22.10M Beat $13.15M Estimate Benzinga

04:01PM EDT Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended June 30, 2020. GlobeNewswire Inc

04:21AM EDT Earnings Scheduled For August 5, 2020 Benzinga

Jul 29, 2020

07:00AM EDT Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at the Canaccord Genuity 40th Annual Growth Conference. The virtual presentation is scheduled for Wednesday, August 12, 2020 at 9:00 a.m. ET. GlobeNewswire Inc

Jul 22, 2020

07:08AM EDT Axogen RECON Clinical Study Completes Target Enrollment Of 220 Subjects Benzinga

07:00AM EDT Axogen RECON Clinical Study Completes Target Enrollment of 220 GlobeNewswire Inc

Jul 15, 2020

07:00AM EDT Axogen, Inc. to Report Second Quarter 2020 Financial Results and GlobeNewswire Inc